Abstract

CT20p is a protein derived from the C-terminus of Bax. It has selective cytotoxicity for cancer cells, such as the sensitive triple-negative MDA-MB-231 breast adenocarcinoma cells, but not normal cells like the resistant MCF-10A epithelial breast cells. To understand the reason for the peptide’s selective toxicity, a "pull-down" experiment with biotinylated CT20p (biotin-CT20p) and whole-cell protein lysates from breast cancer and normal cells were performed. These studies revealed that CT20p binds to a cytosolic protein called chaperonin-containing TCP-1 (CCT), a molecular chaperone that folds actin and tubulin. However, this method could not detect possible rare interactions made by CT20p with mitochondrial proteins. To determine whether CT20p is associated with mitochondrial proteins as part of the mechanism by which it induces cell death, mitochondrial protein lysates from MDA-MB-231 and MCF-10A cells were isolated and a streptavidin-agarose pulldown procedure using biotin-CT20p was performed. Protein interactions were visualized by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using silver staining. The results of the experimental procedure showed that biotin-CT20p did not "pull down" any observable mitochondrial proteins from the sensitive MDA-MB-231 cells, indicating that the peptide may not interact with mitochondrial proteins in breast cancer cells. Rather, the interactions observed with biotin-CT20p were with mitochondrial proteins derived from resistant MCF-10A cells, indicating that these interactions were not driving the cancer-selective cell death process. The absence of CT20p-associated proteins from the mitochondrial lysates of MDA-MB-231 breast cancer cells supports the hypothesis that CT20p, unlike the parent protein, Bax, exerts its cytotoxic effects via a cytosolic protein.

Highlights

  • Therapeutic peptides are a rapidly growing class of drugs that can be used to treat a wide array of diseases and disorders, including cardiovascular disease, infectious disease, and cancer

  • The recently developed cytotoxic peptide, CT20p, could be used to define target molecules and mediators that drive peptide-induced cell death. This information could help develop a companion diagnostic approach to improve the clinical application of CT20p. The objective of this project was to identify mitochondrial proteins that interact with CT20p, which could serve as biomarkers to screen cancer patients for a therapeutic benefit

  • Five hundred μg of mitochondrial lysate from MCF-10A and MDA-MB-231 cells were mixed with 10 μg of biotin or biotin associated with the CT-20 peptide

Read more

Summary

Introduction

Therapeutic peptides are a rapidly growing class of drugs that can be used to treat a wide array of diseases and disorders, including cardiovascular disease, infectious disease, and cancer. Peptides offer greater potency and less non-specific effects than chemically synthesized drugs. There is a need to identify new peptides with cytotoxic activity that could have therapeutic value. One way to discover new peptides is to derive these from proteins with known cytotoxic action that target and inhibit specific organelles or proteins within cells. Peptides that target mitochondria and facilitate the release of intramembrane contents, leading to cell death, could have clinical value. Mitochondria serve key functions in both sustaining life, through energy production by oxidative phosphorylation, and in death, by mediating cytochrome C release and apoptosis

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call